Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-Small Cell Lung Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overOtherSV-001 and SV-002
SFC-SV001, SFC-01-0150-0001-02-CM, SFC-01-0150-001, SFC-SV002, NCT00246727

Trial Description


The primary objective of these two studies is to test the hypothesis that the daily ingestion of a dietary supplement, Selected Vegetables and Herbs Mix (SV), which consists of non-toxic botanicals containing known anti-cancer and/or immune enhancing components, may prolong the survival time of stage IIIB/IV non-small cell lung cancer (NSCLC) patients. Either SV or placebo will be added to their daily diet in a double-blind randomized fashion.

  • Study 1: For those patients who will be receiving standard chemotherapy regimen.
  • Study 2: For those who refuse standard chemotherapy but will receive best supportive care.

Further Study Information

Carcinoma of the lung is the leading cause of cancer related deaths in North America. Non-small Cell Lung Cancer (NSCLC) causes the death of more than 400,000 patients annually in the US and Western Europe. The benefit of conventional therapies, such as chemotherapy and radiotherapy, for unresectable stage IIIB and IV NSCLC patients is marginal; the generally accepted median survival time of late stage patients has remained 4-6 months in the "Supportive Care" group and 6-9 months in the chemotherapy treatment group; the one-year survival is about 20%. A recent paper and an Editorial comment of New Engl J Med concluded that 4 widely used chemotherapy regimens offer only marginal benefits with severe toxicities for advanced NSCLC patients and concluded that “It is time to move on from chemotherapy.”. Because of the poor overall results, NCI concludes that More Effective Treatments for NSCLC Are Urgently Needed.

Ideal Treatment for NSCLC: The toxicity of chemotherapy and side-effects of radiotherapy to the quality of life of the patients have been a major issue in cancer treatments. They not only add misery to the patients' lives, their anticancer activity is severely hindered by its limitation in dosage because higher dosage means more side-effects to the patients. Furthermore, the current chemotherapy for advanced NSCLC is quite expensive, about $50,000 to $100,000 per year. Therefore, an ideal treatment for advanced NSCLC patients should meet the following criteria:

1. Prolong patient survival.

2. Minimal toxicity.

3. Improvement in the patient's quality of life.

4. Relatively inexpensive.

A phytomix consisting of selected vegetables and herbs appears to meet all these criteria. The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.

The Objectives of the proposed studies are to evaluate the benefits and adverse reactions of adding SV to the daily diet of cancer patients who are willing to undergo the chemotherapy (Study 1) or those who refuse chemotherapy (Study 2).

Eligibility Criteria

Inclusion Criteria:

  • Pathological and radiographic documented stage IIIB/IV NSCLC (squamous, adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise specified non-small cell carcinoma) diagnosed less than two months prior to randomization. Recommendations for classifying regional lymph node stations for lung cancer staging, adapted by the American Joint Committee on Cancer and the Union Internationale Contre le Cancer, will be used (Mountain).
  • Patients must have measurable or non-measurable disease as defined in Response Evaluation Criteria in Solid Tumors (RECIST). The baseline measurements/evaluations must be obtained within 4 weeks prior to randomization.
  • Patients must have ECOG performance status of 0-1 and life expectancy >3 months.
  • Patients must be willing to receive chemotherapy after having had explained to them the benefits and risks of being treated with an Food and Drug Administration (FDA)-approved standard chemotherapy regimen (study 1) and after being told about a separate study for patients who refuse this standard chemotherapy (study 2).
  • Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix.
  • Patients must be >18 years of age.
  • Patients must demonstrate the ability and willingness to eat solid food and SV/placebo.
  • Patients must demonstrate the ability and willingness to give informed consent.
  • Patients must demonstrate the ability and willingness to follow the study requirements.

Exclusion Criteria:

  • Laboratory criteria for exclusion within 14 days prior to randomization.

* Liver function: bilirubin > 1.5x upper limit of normal (ULN) and SGOT (AST) > 2.5x ULN.

* Renal function: Serum creatinine >1.5x ULN

* Bone marrow function: white blood cell (WBC) < 4,000/µl; platelet count < 100,000 mm3; neutrophil count < 1,500/mm3.

* Hemoglobin <9 gm/dl for males; < 8.5 gm/dl for females.

  • Unexplained temperature > 38.5° C for any 7 consecutive days or chronic diarrhea defined as > 3 stools/day persisting for 15 consecutive days, within the 30 days prior to randomization.
  • Prior chemotherapy within 5 years and concurrent chemotherapy other than the chemotherapy permitted in this study.
  • Prior radiation to the area of measurable or active tumor.
  • Concurrent hormonal therapy, except for thyroid replacement therapy or glucocorticoids that are necessary for concurrent radiotherapy, adrenal failure, or septic shock. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort.
  • Significant cardiac disease (i.e. uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous year) or serious cardiac arrhythmia requiring medication. Investigators should exercise caution when including patients taking other medications known to affect the conductive system e.g. beta blockers, calcium channel blockers, digoxin or other anti-arrhythmic drugs.
  • Evidence of clinically significant neuropathy (> Grade 1) by physical exam.
  • Patients must not be pregnant or breast-feeding. Female patients of child-bearing potential must have a negative pregnancy test performed within 72 hours prior to randomization. Women of child-bearing potential must agree not to become pregnant while participating in the study.
  • Active acute infection, except for Herpes viruses (cytomegalovirus [CMV], Epstein Barr virus [EBV], herpes zoster virus [HZV], herpes simplex virus 1 [HSV 1]).
  • A serious underlying medical condition other than NSCLC such that life expectancy is less than 2 years.
  • Psychiatric illness that may affect the patient's compliance with the treatment.
  • Current use of illicit drugs, glucocorticoids other than those necessary for concurrent radiotherapy, adrenal failure or septic shock, or other immune-suppressing or immune-modulating drugs. Glucocorticoids for anti-emetic prophylaxis and therapy should only be used as a last resort.
  • A known allergy to one or more components of SV, namely soy beans, mushrooms, mung beans, red dates, scallion, garlic, lentil beans, leek, hawthorn fruit, onions, ginseng, angelica root, Chinese licorice, dandelion root, Senegal root, ginger, olives, sesame seed and parsley.

Trial Contact Information

Trial Lead Organizations/Sponsors

Sun Farm Corporation

  • National Center for Complementary and Integrative Health
Henry S Sacks, MD, Ph.D, Principal Investigator
Henry Sacks, MD, Ph.D
Ph: 212-241-7856
Email: henry.sacks@mssm.edu

Trial Sites


New York
New York

Mount Sinai Medical Center

Henry S Sacks, Md.Ph.d
Ph: 212-241-7856
Email: henry.sacks@mssm.edu

Henry S Sacks, MD, Ph.D
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00246727
Information obtained from ClinicalTrials.gov on 2006-04-11

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.